




Searching News Database: CAR-T
HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
HSMN NewsFeed - 19 Jul 2022
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer
HSMN NewsFeed - 17 Jan 2022
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
HSMN NewsFeed - 28 Oct 2021
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
HSMN NewsFeed - 18 Jan 2021
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 16 Jun 2020
EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors
EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors
HSMN NewsFeed - 7 May 2020
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
HSMN NewsFeed - 12 Mar 2020
F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
HSMN NewsFeed - 16 Dec 2019
Anixa Biosciences Announces Commercial Launch of Cchek(TM) Prostate Cancer Confirmatory Test
Anixa Biosciences Announces Commercial Launch of Cchek(TM) Prostate Cancer Confirmatory Test
HSMN NewsFeed - 22 Nov 2019
Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek(TM) Prostate Cancer Study
Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek(TM) Prostate Cancer Study
HSMN NewsFeed - 28 Oct 2019
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
HSMN NewsFeed - 19 Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
HSMN NewsFeed - 6 May 2019
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
HSMN NewsFeed - 15 Apr 2019
Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
HSMN NewsFeed - 29 Mar 2019
Allogeneic CAR-T Specialists TC BioPharm Appoint Prof John Anderson as Scientific and Medical Director
Allogeneic CAR-T Specialists TC BioPharm Appoint Prof John Anderson as Scientific and Medical Director
HSMN NewsFeed - 25 Feb 2019
Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
HSMN NewsFeed - 7 Feb 2019
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
HSMN NewsFeed - 20 Dec 2018
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
HSMN NewsFeed - 24 Oct 2018
Anixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek(TM) Cancer Diagnostic Test
Anixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek(TM) Cancer Diagnostic Test
HSMN NewsFeed - 1 Oct 2018
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
HSMN NewsFeed - 28 Sep 2018
ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX
ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX
HSMN NewsFeed - 6 Jul 2018
ITUS Corporation Announces Second Commercial Focus for Cchek(TM) will be Breast Cancer
ITUS Corporation Announces Second Commercial Focus for Cchek(TM) will be Breast Cancer
HSMN NewsFeed - 30 Apr 2018
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin(TM) Cytokines
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin(TM) Cytokines
HSMN NewsFeed - 10 Apr 2018
TCR2 Therapeutics Appoints Leading Biotech Analyst Ian Somaiya as Chief Financial Officer
TCR2 Therapeutics Appoints Leading Biotech Analyst Ian Somaiya as Chief Financial Officer
HSMN NewsFeed - 28 Feb 2018
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer
HSMN NewsFeed - 29 Aug 2017
Sorrento Therapeutics, Inc. Submits NDA For ZTlido(TM) Next-Generation Lidocaine Patch
Sorrento Therapeutics, Inc. Submits NDA For ZTlido(TM) Next-Generation Lidocaine Patch
HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
HSMN NewsFeed - 8 Mar 2017
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
HSMN NewsFeed - 9 Jan 2017
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
HSMN NewsFeed - 1 Aug 2016
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
HSMN NewsFeed - 4 Nov 2015
Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer
Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer
HSMN NewsFeed - 2 Jun 2015
ZIOPHARM Announces Caesar J. Belbel, Chief Legal Officer, Appointed Chief Operating Officer
ZIOPHARM Announces Caesar J. Belbel, Chief Legal Officer, Appointed Chief Operating Officer